Anti-tumor activity of gene transfer of the membrane-stable CD40L mutant into lung cancer cells

International Journal of Oncology

Volumn 37, Issue 4, 2010, Pages 935-941

  Xu, Wei ^a   Li, Yan ^a   Wang, Xueli ^a   Wang, Cuiyu ^a   Zhao, Weihong ^a   Wu, Jianqing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cd40 ligand mutant; Gene therapy; Immunotherapy; Lung neoplasms

Indexed keywords

CD40 LIGAND; MUTANT PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GENE THERAPY; CELL ACTIVATION; CELL CYCLE PHASE; CONTROLLED STUDY; DENDRITIC CELL; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; RECOMBINANT PLASMID;

ADENOCARCINOMA; APOPTOSIS; BASE SEQUENCE; CD40 LIGAND; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; COCULTURE TECHNIQUES; DENDRITIC CELLS; HUMANS; LUNG NEOPLASMS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PROTEIN CONFORMATION; PROTEIN STABILITY; TIME FACTORS; TRANSFECTION;

EID: 77956546376     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000744     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
2. Berhoune M, Banu E, Scotte F, Prognon P, Oudard S and Bonan B: Therapeutic strategy for treatment of metastatic non-small cell lung cancer. Ann Pharmacother 42: 1640-1652, 2008.
3. Tüting T, Storkus WJ and Lotze MT: Gene-based strategies for the immunotherapy of cancer. J Mol Med 75: 478-491, 1997.
4. Loskog AS and Eliopoulos AG: The Janus faces of CD40 in cancer. Semin Immunol 21: 301-307, 2009.
5. Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE and Kipps TJ: CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96: 2917-2924, 2000.
6. Biagi E, Rousseau R, Yvon E, et al: Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res 11: 6916-6923, 2005.
7. Dessureault S, Noyes D, Lee D, et al: A phase-I trial using a universal GM-CSF-producing and CD154-expressing bystander cell line (GM.CD154) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann Surg Oncol 14: 869-884, 2007.
8. Vonderheide RH, Dutcher JP, Anderson JE, et al: Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 19: 3280-3287, 2001.
9. Gomes EM, Rodrigues MS, Phadke AP, et al: Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin Cancer Res 15: 1317-1325, 2009.
10. Pietravalle F, Lecoanet-Henchoz S, Blasey H, et al: Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J Biol Chem 271: 5965-5967, 1996.
11. Goules A, Tzioufas AG, Manousakis MN, Kirou KA, Crow MK and Routsias JG: Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun 26: 165-171, 2006.
12. Ferroni P, Santilli F, Guadagni F, Basili S and Davì G: Contribution of platelet-derived CD40 ligand to inflammation, thrombosis and neoangiogenesis. Curr Med Chem 14: 2170-2180, 2007.
13. Davies CC, Mason J, Wakelam MJ, Young LS and Eliopoulos AG: Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. J Biol Chem 279: 1010-1019, 2004.
14. Masuta Y, Kato K, Tomihara K, et al: Gene transfer of non-cleavable cell surface mutants of human CD154 induces the immune response and diminishes systemic inflammatory reactions. J Immunother 30: 694-704, 2007. (Pubitemid 47480753)
15. Wang TL, Huang JA, Yu GH, Mao YX, Wang GJ and Zhang XG: Biological effects of soluble CD40 ligand on lung cancer cell line A549 and its mechanism. Ai Zheng 23: 1278-1282, 2004.
16. Berges C, Naujokat C, Tinapp S, et al: A cell line model for the differentiation of human dendritic cells. Biochem Biophys Res Commun 333: 896-907, 2005.
17. Jiang YF, He Y, Gong GZ, Chen J, Yang CY and Xu Y: Construction of recombinant eukaryotic expression plasmid containing murine CD40 ligand gene and its expression in H22 cells. World J Gastroenterol 11: 182-186, 2005.
18. Wagner AH, Güldenzoph B, Lienenlüke B and Hecker M: CD154/CD40-mediated expression of CD154 in endothelial cells: consequences for endothelial cell-monocyte interaction. Arterioscler Thromb Vasc Biol 24: 715-720, 2004.
19. Tomihara K, Kato K, Masuta Y, et al: Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells. Int J Cancer 120: 1491-1498, 2007.
20. Georgopoulos NT, Steele LP, Thomson MJ, Selby PJ, Southgate J and Trejdosiewicz LK: A novel mechanism of CD40-induced apoptosis of carcinoma cells involving TRAF3 and JNK/AP-1 activation. Cell Death Differ 13: 1789-1801, 2006.
21. Koppold B, Sauer G, Büning H, et al: Efficient gene transfer of CD40 ligand into ovarian carcinoma cells with a recombinant adeno-associated virus vector. Int J Oncol 26: 95-101, 2005.
22. Vardouli L, Lindqvist C, Vlahou K, Loskog AS and Eliopoulos AG: Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas. Cancer Gene Ther 16: 848-860, 2009.
23. Dzojic H, Loskog A, Tötterman TH and Essand M: Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. Prostate 66: 831-838, 2006. (Pubitemid 43749207)
24. Iida T, Shiba H, Misawa T, Ohashi T, Eto Y and Yanaga K: Adenovirus-mediated CD40L gene therapy induced both humoral and cellular immunity against rat model of hepatocellular carcinoma. Cancer Sci 99: 2197-2103, 2008.
25. Serba S, Schmidt J, Wentzensen N, Ryschich E and Märten A: Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma. Gut 57: 344-351, 2008.
26. Sun Y, Peng D, Lecanda J, et al: In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Gene Ther 7: 1467-1476, 2000.
27. Lindqvist C, Sandin LC, Fransson M and Loskog A: Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition. J Immunother 32: 785-792, 2009.
28. Wu JQ, Zhao WH, Li Y, Zhu B and Yin KS: Adeno-associated virus mediated gene transfer into lung cancer cells promoting CD40 ligand-based immunotherapy. Virology 368: 309-316, 2007.
29. von Euler H, Sadeghi A, Carlsson B, et al: Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J Immunother 31: 377-384, 2008.
30. Tomihara K, Kato K, Masuta Y, et al: Gene transfer of CD40-ligand o dendritic cells stimulates interferon-gamma production to induce growth arrest and apoptosis of tumor cells. Gene Ther 15: 203-213, 2008.
31. Vardouli L, Lindqvist C, Vlahou K, Loskog AS and Eliopoulos AG: Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas. Cancer Gene Ther 16: 828-860, 2009.
32. Elmetwali T, Searle PF, McNeish I, Young LS and Palmer DH: CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus. Mol Cancer 9: 52, 2010.
33. Hoffmann TK, Meidenbauer N, Müller-Berghaus J, Storkus WJ and Whiteside TL: Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-priming capability of human dendritic cells internalizing apoptotic cancer cells. J Immunother 24: 162-171, 2001. (Pubitemid 32183062)
34. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y and Noelle RJ: Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 229: 152-172, 2009.